Member Exclusive

Epigenetics and Alzheimer’s: Phase I trials begin for epigenetic drug ORY-2001

First subject dosed in Phase I healthy volunteer study to evaluate Oryzon’s (Barcelona, Spain) oral epigenetic drug for the treatment of Alzheimer’s disease.

Go to the profile of Stella Bennett
Apr 07, 2016
0
0

Please sign in or register for FREE to view this content

Register to EpigenomicsNet – the epigenetics and epigenomics network

EpigenomicsNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.

Register

No comments yet. Start the conversation...